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• We tested opioid injection maintenance treatment for long-term heroin dependence.
• Participants received injectable diacetylmorphine or hydromorphone for 12 months.
• We examined predictors of past-month non-use of illicit heroin during treatment.
• Independent effect of several concurrent factors besides the injection opioid dose.
• This suggests beneﬁts from the clinic that go beyond the provision of medication.Abbreviations:NAOMI, North AmericanOpiateMedica
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Aims: To investigate baseline and concurrent predictors of non-use of illicit heroin among participants
randomized to injectable opioids in the North American Opiate Medication Initiative (NAOMI) clinical trial.
Methods: NAOMI was an open-label randomized controlled trial comparing the effectiveness of injectable
diacetylmorphine and hydromorphone for long-term opioid-dependency. Outcomeswere assessed at base-
line and during treatment (3, 6, 9, 12 months). Days of non-use of illicit heroin in the prior month at each
follow-up visit were divided into three categories: Non-use; Low use (1 to 7 days) and High use (8 days
or more). Tested covariates were: Sociodemographics, Health, Treatment, Drug use and illegal activities.
Mixed-effect proportional odds models with random intercept for longitudinal ordinal outcomes were
used to assess the predictors of the non-use of illicit heroin.
Results: 139 participants were included in the present analysis. At each follow-up visit, those with non-use
of illicit heroin represented 47.5% to 54.0% of the sample. Fewer days of cocaine use (p= 0.074), fewer days
engaged in illegal activities at baseline (p b 0.01) and at each visit (p b 0.01), less money spent on drugs
(p b 0.001), days with injection opioid or oral methadone treatment (p b 0.001) and total mg of injectable
opioids taken (p b 0.001), independently predicted lower use of illicit heroin.
Conclusions: The independent effect of several concurrent factors besides the injection of opioid dose
suggests beneﬁts from the clinic that go beyond the provision of the medication alone. Thus, this supervised
model of care presents an opportunity to maximize the beneﬁcial impact of medical and psychosocial compo-
nents of the treatment on improving outcomes associated with non-use of illicit heroin.© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).tion Initiative;MMT,methadonemaintenance treatment; DAM, diacetylmorphine; HDM, hydromorphone.
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critical public health problem in Canada and the world. Among long-
term users, abstinence from opioids (licit or illicit) is difﬁcult to sustain
over time and therefore abstinence-oriented therapies show relatively
low efﬁcacy (De Jong, Roozen, van Rossum, Krabbe, & Kerkhof, 2007).
Opioid agonist substitution has been shown to be the most effective
treatment option (Van den Brink & Haasen, 2006), in particular oral
methadonemaintenance treatment (MMT) iswidely used and accepted
in western countries. Although evidence shows that MMT is highly
effective (Amato et al., 2005), some opioid dependent individuals are
not attracted to or do not beneﬁt from this therapy (Goldstein, Deren,
Kang, Des Jarlais, &Magura, 2002; Termorshuizen et al., 2005), relapsing
into using illicit street heroin, even while receiving methadone treat-
ment (Best et al., 1999). For individuals for whom at a given time absti-
nence oriented treatment and oral methadone treatments are not
effective, alternative therapeutic options have been tested, such as
medically prescribed pharmaceutical-grade heroin (diacetylmorphine,
DAM).
Studies in Europe and Canada ascertained the efﬁcacy of supervised
medically prescribed DAM in specialized clinics for long-term opioid in-
jectors who continue using street opioids despite the available treat-
ments (Haasen et al., 2007; March, Oviedo-Joekes, Perea-Milla, &
Carrasco, 2006; Oviedo-Joekes et al., 2009; Rehm et al., 2001; Strang
et al., 2010; van den Brink et al., 2003). Moreover, an independent sys-
tematic review of eight randomized clinical trials involving 2007 partic-
ipants has concluded that treatment with DAM (with or without co-
prescribed ﬂexible dosages of methadone), compared to oral metha-
done, helps patients to remain in treatment and to reduce use of illicit
drugs (Ferri, Davoli, & Perucci, 2011). Upon the demonstrated effective-
ness of DAM in controlled trials, studies in Europe have explored the
response to treatment among those who were eligible to continue re-
ceiving it. For example, in the Netherlands, 149 participants in the clin-
ical trials were eligible to continue receiving DAM after ﬁnishing the
study. Results showed that among those patients retained in treatment,
4-year response rates (amultidomain outcomemeasure (van den Brink
et al., 2003)) were 90% (Blanken, Hendriks, van Ree, & van den Brink,
2010).
The Canadian study (NAOMI, North American Opiate Medication
Initiative), conducted between 2005 and 2008, was a randomized
controlled trial testing the effectiveness of injectable DAM, com-
pared to oral MMT, in the Canadian context (Oviedo-Joekes et al.,
2009). After twelve months, 67.0% of the participants receiving
DAM responded to treatment (based on a multidomain outcome)
compared to 47.8% in the methadone group (RR = 1.40; 95%
CI = 1.11–1.77; p= 0.004). The respective addiction treatment re-
tention rates in the DAM and MMT groups were 87.8% and 54.1%
(RR of 1.62; CI 95% = 1.35–1.95; p b 0.001). Analysis of baseline
factors of treatment outcomes at 12 months indicated that after
adjusting for these variables, treatment with diacetylmorphine remained
the only signiﬁcant predictor (Oviedo-Joekes et al., 2009). An additional
small group in the injection arm received hydromorphone (HDM) on
a double blind basis, showing almost identical favorable outcomes
when compared with DAM (Oviedo-Joekes, Guh, Brissette, Marsh, et al.,
2010).
However, the latter analysis utilized baseline predictors only and
focused on the multidomain clinical outcome and retention in the
prior two weeks at twelve months. In the present analysis, we con-
sider past month non-use of illicit heroin as the favorable outcome
on an ongoing basis through the trial. In clinical practice, correlates
of addiction treatment favorable outcomes are important to be
taken into consideration when making decisions about starting or
continuing an intervention (Ciraulo, Piechniczek-Buczek, & Iscan,
2003). In the case of treatment with diacetylmorphine, several stud-
ies have identiﬁed long-term outcomes (Blanken et al., 2010; Frick,Wiedermann, Schaub, Uchtenhagen, & Rehm, 2010; Oviedo-Joekes,
March, Romero, & Perea-Milla, 2010; Verthein et al., 2008), however,
little is known regarding predictors of treatment outcomes. In
the present study we aim to investigate baseline and concurrent
predictors of non-use of illicit heroin during the 12 month NAOMI
study period among participants receiving injectable opioids (either
diacetylmorphine or hydromorphone).2. Methods
NAOMI was an open-label, phase III randomized clinical trial. Partic-
ipants' proﬁle, study design, methodology and results of the parent
study have been published elsewhere (Oviedo-Joekes et al., 2009;
Oviedo-Joekes, Guh, Brissette, Marchand, et al., 2010; Oviedo-Joekes,
Guh, Marsh, Brissette, et al., 2010; Oviedo-Joekes et al., 2008). Brieﬂy,
eligible participants were at least 25 years of age, with a minimum of
5 years of opioid dependence, current daily injection of opioids, at
least two prior treatment attempts for opioid dependence (including
at least one MMT attempt), and no enrolment in MMT within the
prior 6 months. A total of 251 individuals were randomized to receive
oral methadone (n = 111) or injectable DAM (n = 115). In addition
to the 115 participants receiving DAM, a small group of 25 participants
received injectable HDM on a double blind basis with DAM, to detect
illicit heroin use in urinalysis (Oviedo-Joekes, Guh, Brissette, Marsh,
et al., 2010).
Injectable treatment was provided up to three times daily under the
supervision of nursing staff. HDM and DAM doses were prescribed in
DAM equivalents, to maintain the blinding (Oviedo-Joekes, Marsh,
Guh, Brissette, & Schechter, 2011). The study protocol allowed individ-
ualized doses, with a four day titration protocol and a maximum of
400 mg per dose and 1000 mg per day. When a participant was absent
for more than 3 consecutive days (9 sessions) and less than or equal to
7 days (21 sessions and under), a third of the prescribed dose plus
25 mg was dispensed at each following dose until the tolerated dose
was achieved. When a participant missed more than 7 consecutive
days (22 sessions), the prescription was canceled, the induction phase
was then restarted as per protocol.
Participants were offered psychosocial services and primary care on
site and all services were delivered in a patient-centered fashion
(Canada, 2002).Medicationswere provided for 12 months. Since inject-
able medications were not licensed for addiction treatment, an
additional 3-month period was provided to taper and transition those
in the injection group to other treatment modalities (primarily MMT).
All participants provided written informed consent and the study was
approved by the University of British Columbia/Providence Health
Care and Centre de Recherche du Centre Hospitalier de l'université
de Montréal research ethics boards.
A research team, independent of the clinic services, obtained out-
come evaluations at baseline and follow-up (3, 6, 9, 12 months) using
the European Addiction Severity Index (Kokkevi & Hartgers, 1995),
theMaudsley Addiction Proﬁle (Marsden et al., 1998) andhealth related
quality of life measures (Brooks, 1996). Data on dose and treatment
compliance were obtained from the study clinic database. In this study
we included participants who were randomized to the injectable arm
to receive either DAM or HDM and did not withdraw their consent
(n = 139; DAM = 114; HDM = 25). A prior study has demonstrated
that these two groups had similar outcomes, therefore they are
combined for the present analysis (Oviedo-Joekes, Guh, Brissette,
Marsh, et al., 2010). Treatment effectiveness was deﬁned as days
of non-use of illicit heroin in the prior 30 days and, among those
receiving hydromorphone, no positive urinalysis for morphine or
6 monoacetylmorphine. Because this was not normally distributed,
we chose to divide days of Illicit heroin use in the prior 30 days, at
each follow-up visit, into three categories: 1 — Non-use = 0 days in
the prior month and no positive morphine or monoacetylmorphine
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7 days and 3 — High use = 8 days or more.2.1. Analysis
Covariates were classiﬁed into four groups: 1) sociodemographics:
site and aboriginal ancestry (Vancouver Aboriginal, Vancouver
Non-aboriginal, Montreal), gender, age, education, marital status,
stable housing. 2) Health: chronic medical problem that interferes
with life, days with medical symptoms in the prior month, health
related quality of life. 3) Drug use and illegal activities in the prior
month: cocaine (baseline and follow-up), cannabis (follow-up),
less than $300 CND spent on drugs, involvement in illegal activities
(baseline and follow-up; any illegal activity for proﬁt, excludes
drug consumption or possession); and 4) treatment in the prior
month: days with any opioid maintenance treatment (i.e., injectable
DAM/HDM or MMT), days with injection treatment, percentage of
missed injection sessions (denominator = total number of sessions
with an injectable opioid prescription in the prior month ranging from
0 to 90 with a median of 90 [IQR: 47–90] sessions), maximum daily
DAM equivalent dose prescribed total amount in mg of DAM mg used
in the prior 30 days.
Mixed-effect proportional odds models with random intercept for
longitudinal ordinal outcomes were used to assess the predictors of
the use of illicit heroin. The proportional odds models for an ordinal
response of K = 3 categories in this study assumes that the effect of a
covariate is proportional across the model's K − 1 cumulative odds.
Model building was performed in two steps as described below.
First step involved the selection of covariates within the above-
mentioned four groups of variables. For a variable to be considered in
the model within the group, the variable must have a have a p-value
≤0.2 (i.e. an entry signiﬁcance level of 0.2). We then evaluated the
Akaike information criterion (AIC) of all different possible combinations
of variables within the same group and selected the model with the
smallest AIC (the smaller the AIC, the better the model ﬁt). Using this
variable selection method, we attempted to avoid over-adjustment
and addressed the issue that the variables within the same group
were usually highly correlated (i.e., multicolinearity). The next step
was to construct the ﬁnal model using the variables selected from
each group in the ﬁrst step. The selection criteria for the ﬁnal model
were a p value of ≤0.1 for each individual variable and smaller AIC.
Site and aboriginal ancestry, age and genderwere adjusted in all models
in both steps. Missing non-use of illicit heroin data at 3, 6, 9 and
12 months of follow-up visits were: 4 (2.8%); 6 (4.3%); 7 (5.0%); 3
(2.2%); those cases were assigned to the high use of illicit heroin
group. Multiple imputation for other missing data was performed toTable 1
Past month use of illicit heroin at each follow-up assessment.
Non-use of illici
3 months N (%) 67 (48.2%)
Days of illicit heroin use: mean (SD) 0
6 months N (%) 66 (47.5%)
Days of illicit heroin use: mean (SD) 0
9 months N (%) 75 (54.0%)
Days of illicit heroin use: mean (SD) 0
12 months N (%) 69 (49.6%)
Days of illicit heroin use: mean (SD) 0
1) Number and percentage; 2) mean and standard deviation.
Participants who missed a follow-up visit were assigned to the high use group; N at 3, 6, 9 and
a Self-reported zero days of illicit heroin use in the prior 30 days and no positive urinalysis f
b Self reported one to seven days of illicit heroin use in the prior 30 days.
c Self reported eight to thirty days of illicit heroin use in the prior 30 days.assess the robustness of the results. Data analyses were conducted
using SAS version 9.3.3. Results
The baseline characteristics of the NAOMI study participants have
been described and discussed elsewhere (Oviedo-Joekes et al., 2008).
Participants in the injection arm were 50 (36.0%) female, Aboriginal
ethnicity 32 (23%), and average age 40.0 (SD= 7.8). Themean average
number of days using illicit heroinwere 26.6 (SD= 7.5), illicit activities
15.0 (SD = 12.6) and cocaine 16.4 (SD = 12.5). A total of 77 (55.4%)
participants had chronic medical problem that interferes with life and
the mean prior methadone attempts was 3.1 (SD = 1.7).
At every evaluation time (3, 6, 9 and 12 months; Table 1), thosewith
past month non-use of illicit heroin represented half of the sample
(47.5% to 54.0%) and low illicit heroin use comprised between 23.7%
and 30.2%. The average days of illicit heroin for low use of illicit heroin
were between 2.45 and 2.09 (SD=1.26 and 1.89, respectively). High il-
licit heroin use was reported between 20.9% and 23.7% of the sample,
with average days of use of illicit heroin between 19.00 and 22.88
(SD = 8.78 and 8.43, respectively).
After adjusting by site, aboriginal ancestry, gender and age (none of
these were signiﬁcant), the following variables showed associations
with p values lower than 0.2 (i.e., the pre-deﬁned entry signiﬁcance
level in Step 1 model selection): days in the prior month using cocaine
at baseline and at each visit; days in the prior month engaged in illegal
activities at baseline and at each visit; money spent on drugs (less than
$300 CND); dayswithmedical problems; dayswith any treatment; days
with injection treatment; maximum DAM equivalent dose prescribed;
and total DAM equivalentmg taken. These variables were being consid-
ered while the ﬁnal model was being constructed. The ﬁnal model is
shown in Table 2 where the last two columns presented the estimated
beta-coefﬁcient (representing the increase in log-odds of having lower
use of illicit heroin per unit increase of the independent variable while
other covariates in the model are held constant) and the estimated
odds ratio of having lower use illicit heroin use. For example, the
model shows that the odds of a participant who spent b$300 on
drugs in the prior month to have non-use of illicit heroin was 2.78
times greater than that who spent ≥$300, given that the other vari-
ables in the model are held constant. Similarly, for a day increase
with any treatment in the prior month, the odds of having non-use
of illicit heroin vs. low and high uses of illicit heroin are 1.08 times
greater given that the other variables in the model are held constant.
The ﬁnal model showed that days of cocaine use in the prior month,
days in the prior month engaged in illegal activities at baseline and at
each visit, money spent on drugs (less than $300 CND) days with anyt heroina Low use of illicit heroinb High use of illicit heroinc
42 (30.2%) 30 (21.6%)
3.07 (1.67) 21.85 (8.05)
40 (28.8%) 33 (23.7%)
2.45 (1.26) 22.41 (7.44)
33 (23.7%) 31 (22.3%)
3.09 (1.89) 19.00 (8.78)
41 (29.5%) 29 (20.9%)
2.90 (1.70) 22.88 (8.43)
12 months visits were: 4 (2.8%); 6 (4.3%); 7 (5.0%); 3 (2.2%).
or morphine or 6 monoacetylmorphine among those receiving hydromorphone.
Table 2
Adjusted model for predictors of past month non-use of illicit heroin.
Variables1, 2 Non-use of illicit heroin
(0 day)a
Low use of illicit heroin
(1–7 days)b
High use of illicit heroin
(≥8 days)c
Estimate
(SE)d
OR of having lower
use of illicit heroin
(95% CI)
b300 Money spent on drugs in the prior month 1.02 (0.26) 2.78*** (1.66–4.68)
3 months 48 (64.9%) 24 (32.4%) 2 (2.7%)
6 months 36 (62.1%) 18 (31.0%) 4 (6.9%)
9 months 47 (81.0%) 8 (13.8%) 3 (5.2%)
12 months 46 (75.4%) 15 (24.6%) 0 (0.0%)
Days of cocaine use in the prior month −0.02 (0.01) 0.98* (0.96–1.00)
3 months 10.79 (10.95) 12.38 (10.62) 19.58 (12.91)
6 months 11.27 (11.56) 17.98 (12.43) 21.41 (10.62)
9 months 11.28 (11.85) 18.55 (12.45) 20.13 (12.20)
12 months 9.87 (11.94) 18.05 (11.14) 22.69 (11.54)
Days with illegal activities at baseline −0.03 (0.01) 0.97** (0.94–0.99)
3 months 11.87 (12.70) 14.90 (11.68) 22.00 (11.03)
6 months 10.80 (12.22) 15.60 (11.04) 22.55 (11.70)
9 months 12.32 (12.51) 15.33 (11.14) 21.00 (12.50)
12 months 13.01 (12.47) 14.27 (11.61) 20.62 (12.97)
Days with illegal activity in the prior month −0.03 (0.01) 0.97** (0.95–0.99)
3 months 3.01 (8.39) 5.40 (10.17) 17.04 (12.88)
6 months 3.56 (8.14) 10.18 (11.52) 13.67 (12.90)
9 months 4.60 (9.20) 10.39 (12.62) 14.75 (13.49)
12 months 4.75 (9.33) 8.15 (12.41) 18.85 (12.79)
Days with any treatment in the prior monthe 0.08 (0.02) 1.08*** (1.05–1.12)
3 months 28.57 (5.21) 28.40 (5.09) 19.73 (12.12)
6 months 28.18 (6.28) 29.00 (2.16) 19.06 (13.49)
9 months 28.21 (5.78) 28.48 (5.26) 18.26 (13.88)
12 months 28.81 (5.13) 26.68 (8.84) 13.03 (14.06)
Total mg used in DAM equivalent 0.08f (0.02) 1.08***f (1.03–1.14)
3 months 8946.00 (5997.47) 7221.77 (3973.50) 5772.50 (6096.64)
6 months 9882.73 (6476.15) 8171.50 (5921.75) 5172.27 (5907.14)
9 months 9652.82 (7061.59) 7934.24 (6542.99) 4926.67 (6022.87)
12 months 9133.09 (7007.28) 7287.11 (6226.70) 2439.31 (4331.56)
P values: *** b .001; ** b .01; * = 0.074.
DAM = diacetylmorphine.
SE = standard error.
OR = odd ratio.
a Self-reported zero days of illicit heroin use in the prior 30 days and no positive urinalysis for morphine or 6 monoacetylmorphine among those receiving hydromorphone.
b Self reported one to seven days of illicit heroin use in the prior 30 days.
c Self reported eight to thirty days of illicit heroin use in the prior 30 days.
d AIC = 902.50; adjusted by: site, aboriginal ancestry, gender and age. All with p values above 0.6.
e Any treatment refers to opioid maintenance with either injectable diacetylmorphine, hydromorphone or oral methadone.
f The variablewas re-scaled to totalmg used inDAMequivalent in 1000 mg. Therefore, the estimated coefﬁcient represented the increase in log-odds per 1000 mg increase in the use of
DAM equivalent.
1 Number and percentage.
2 Mean and standard deviation.
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predicted lower use of illicit heroin. The analysis from multiple im-
putation yielded very similar results as the percentage of missing
data is small (4%).
4. Discussion
The present study aimed at identifying predictors of past month
non-use of illicit heroin among participants in a clinical trial that receive
injectable diacetylmorphine or hydromorphone. At each evaluation
point, most of the participants were either not using illicit heroin or
using less than 7 days in the prior month. Fewer days involved in illicit
activities, at baseline and past month, less ongoing cocaine use and
money spent on illicit drugs as well as more days engaged in treatment
(injectables or MMT) and higher dosage of diacetylmorphine or
hydromorphone received in the prior month, independently predicted
non- or low use of illicit heroin.
Patients that reduce their illicit drug use after entering addiction
treatment, have shown a decline in their involvement in for-proﬁt ille-
gal activities (Jofre-Bonet & Sindelar, 2001). This is also the case when
receiving treatment with injectable diacetylmorphine (Brehmer &
Iten, 2001; Frick et al., 2010; Guttinger, Gschwend, Schulte, Rehm, &
Uchtenhagen, 2003; Lobmann & Verthein, 2009; Verthein, Schafer, &Degkwitz, 2013), indicating a possible protective effect against criminal
activity (Ferri et al., 2011). Our study indicates that involvement in
illicit activities before starting treatment also independently predicts
illicit heroin use in the past month after starting treatment. It is possible
that decades of involvement in illegal activities created health inequal-
ities that impact treatment outcomes and that might not be able to be
reversed over 12 months of injected opioid maintenance treatment.
Money spent on drugs could be an indicator of daily quantities of
drug consumed that would not necessary be signiﬁcant if measured as
days of use in the prior month. Some studies have identiﬁed cocaine
and other stimulant use as associated with poorer outcomes on opioid
substitution treatment (Bravo et al., 2010; Deck & Carlson, 2005;
DeMaria, Sterling, &Weinstein, 2000), although there are several possi-
ble patterns of co-use (Leri, Bruneau, & Stewart, 2003). Non- or low use
of street heroin could be an indicator of an overall favorable response to
addiction treatment resulting in less contact with street drug environ-
ment, therefore decreased use of cocaine. However, we should also con-
sider that in timeswhen reducing theuse of cocainewas not possible for
a patient, thismight result in an increased use of illicit heroin. Combined
with the independent relationshipwith pastmonth engagement in illic-
it activities, these results suggest that those illicit activities are mostly
aimed at acquiring drugs, as described in prior studies (van der
Zanden, Dijkgraaf, Blanken, van Ree, & van den Brink, 2007). Overall
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saving funds otherwise spent ondrugs, but limiting their illicit activities.
Consistent with the literature, days on opioid maintenance treat-
ment in the prior 30 days was a predictor of non-use of illicit heroin. It
is important to notice that days on treatment mostly referred to treat-
ment with injectable opioids and in some few cases participants
transitioned within the trial to oral methadone, totally or partially
(Oviedo-Joekes et al., 2009). It is noteworthy that higher total DAM
equivalent dose received in the prior month was also independently
associated with lower use of illicit heroin. Attending for treatment con-
sistently and DAM equivalent dose received are related given that con-
tinuity in treatment is necessary to maintain optimal doses for safety
reasons. Although we cannot establish a causal relationship, these data
suggest that higher doses of DAM equivalent are necessary to observe
non-use of illicit heroin. Patients require a range of doses and our data
as well as other studies indicate that in general, those on higher doses
do better (Donny, Brasser, Bigelow, Stitzer, & Walsh, 2005). Although
these ﬁndings suggest that the dose must be increased and maintained
in an individualized optimal level, this should be done in a manner that
is safe. Therefore, patients who attend sporadically present a challenge
to be maintained on an optimal dose. The supervised model of care in
which this treatment is offered presents an opportunity for frequent
medical and psychosocial interventions on improving treatment com-
pliance, thusmaintaining patients with optimal doses. The independent
effect of attendance for treatment reinforces this but also suggests ben-
eﬁts from the clinic that go beyond the provision of the medication
alone.
The NAOMI clinical trial was not speciﬁcally designed to investigate
ongoing predictors of non-use of illicit heroin among participants eligi-
ble to receive injectable opioids; thus the present studymight be under-
powered and no causal relationships can be established. However the
present analysis tested factors associated with non-use of illicit heroin
and suggests opportunities for improvement of this treatment model.
Also, the NAOMI sample is a very homogeneous group of opioid depen-
dent individuals who had several previous treatment attempts and had
used street heroin for many years; thus our results may not be general-
izable to populations of opioid-dependent patients with different
proﬁles and treatment histories. Having said that, it is clear that this
patient population is the one for whom treatments such as injectable
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